Last reviewed · How we verify

NCT00353561

Diabetes Mellitus and Vulvovaginal Candidiasis: Prevalence of Infection and Its Rationale Management

Completed Phase 3 Last updated 21 May 2008
What this trial tests

Phase 3 trial testing Boric in Diabetes Mellitus in 100 participants. Completed in 1 April 2006.

Timeline
1 June 2004
Primary endpoint
1 April 2006
1 April 2006

Quick facts

Lead sponsorIndian Council of Medical Research
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment100
Start date1 June 2004
Primary completion1 April 2006
Estimated completion1 April 2006
Sites1 location across India

Drugs / interventions tested

Conditions studied

Sponsor

Indian Council of Medical Research

Who can join

Adults 18 to 66, female only, with Diabetes Mellitus or Vulvovaginal Candidiasis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

Clinical and mycological response to oral fluconazole and boric acid suppositories was assessed in patients with diabetes mellitus and vulvovaginal candidiasis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

Other Indian Council of Medical Research trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00353561.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing